A1C Almanac

Main Page

When Prestige Wellness Meets the Algorithm

Posted

by

dr Karunia Valeriani Japar

Table of Contents
Category:
Tags: , , , ,

Keywords: Prestige Medicine, Precision Health, Metabolic Prevention, Cardiometabolic Resilience, Biohacking

The Age of “Prestige Medicine”

In the contemporary landscape of wellness and longevity, “prestige medicine” has emerged as a subtle yet pervasive status symbol, characterized by executive health check-ups, luxury clinics, high-end supplements, and boutique biohacking programs positioned as expedited pathways to extended health span. These offerings often emphasize exclusivity, advanced diagnostics, and experiential elements, appealing to affluent individuals seeking optimization amid rising awareness of metabolic and aging-related risks.

In stark contrast, precision medicine also termed personalized medicine represents a paradigm that leverages an individual’s genomic profile, environmental exposures, lifestyle factors, and real-time biomarkers to tailor prevention, diagnosis, and therapeutic strategies, thereby departing from the traditional one-size-fits-all approach. This framework has gained traction in fields like oncology and cardiology, where inter-individual variability in drug response and disease susceptibility demands customized interventions.

Within cardiometabolic and aging medicine, the divergence between prestige and precision is particularly salient: opulent interventions may deliver marginal or illusory benefits absent a foundation in mechanistic pathophysiology and individualized data integration. Lavish experiences, while psychologically gratifying, frequently overlook foundational risk modifiers such as glycemic control, lipid dynamics, and inflammaging trajectories, which drive the majority of preventable morbidity.

This article delineates the tensions inherent in prestige-driven versus precision-oriented models of wellness and metabolic prevention, while proposing an actionable framework to empower clinicians, health tech innovators, and patients in discerning and prioritizing interventions that demonstrably advance cardiometabolic resilience and longevity.

Prestige vs Precision in Practice

Precision medicine, frequently conflated with personalized medicine, constitutes a systematic approach to stratify individuals into subpopulations exhibiting distinct susceptibilities, prognoses, or therapeutic responses, thereby enabling tailored preventive, diagnostic, and interventional strategies. This methodology hinges on integrating multidimensional data, encompassing genomics, epigenomics, metabolomics, and environmental determinants to anticipate disease trajectories and optimize outcomes, marking a departure from empirical, population-averaged paradigms. In clinical practice, such stratification facilitates nuanced decision-making, as exemplified by pharmacogenomic-guided dosing in cardiovascular therapeutics or risk-adjusted screening protocols in oncology [1,2,3,4].

In the domain of preventive cardiometabolic care, precision medicine manifests through targeted modalities including genomic variant analysis (e.g., APOC3 loss-of-function alleles modulating triglyceride metabolism), metabolomic profiling of lipid subfractions and glycemic excursions, continuous glucose monitoring (CGM) for real-time phenotyping of insulin dynamics, digital biomarkers from wearables capturing activity chronotypes, and contextual lifestyle data to refine nutritional timing, exercise prescription, and pharmacotherapy selection. These tools collectively empower a granular optimization of interventions, such as chrononutrition protocols calibrated to an individual’s circadian misalignment or statin intensification based on polygenic risk scores, yielding superior risk attenuation compared to generic guidelines [5,6,7].

Within this discourse, “prestige medicine” is employed descriptively rather than pejoratively to denote high-cost, conspicuous interventions. often technology-laden or luxury-branded, that prioritize experiential exclusivity and perceptual sophistication over rigorously validated efficacy. Such offerings, including bespoke longevity retreats or panoramic imaging suites, may engender psychological benefits like enhanced adherence through aspirational appeal, yet their utility remains contingent on alignment with empirical risk architectures rather than inherent superiority [8,9].

The pivotal inquiry, therefore, transcends simplistic valorization or condemnation of prestige modalities; rather, it interrogates their systematic congruence with an individual’s bespoke risk profile, biological idiosyncrasies, and ecological realities, the sine qua non of precision medicine. Absent this fidelity, even ostensibly elite care risks devolving into performative optimization, underscoring the imperative for evidence hierarchies that privilege mechanistic personalization over opulent generality [10].

The Limits of Prestige Medicine in Wellness and Aging

Many prestige interventions in wellness and aging, such as advanced whole-body imaging, expansive biomarker panels, or comprehensive “longevity packages” often prioritize diagnostic comprehensiveness over integration with validated risk stratification tools, evidence-based thresholds, or structured follow-up protocols. These offerings, while technologically impressive, frequently generate incidental findings or data overload without delineating actionable pathways to mitigate core drivers of cardiometabolic decline, such as atherogenic dyslipidemia or insulin resistance. Consequently, their clinical yield diminishes when decoupled from hierarchical risk assessment models like the Framingham Risk Score or ASCVD pooled cohort equations, which emphasize probabilistic forecasting over exhaustive screening [11,12,13,14].

Population-level data underscore that traditional modifiable risk factors—including hypertension, dyslipidemia (particularly LDL cholesterol), adiposity (BMI or waist circumference), tobacco exposure, sedentary behavior, and impaired glycemic homeostasis collectively account for over 70-90% of attributable risk in metabolic and cardiovascular disease, with robust attenuation achievable through targeted lifestyle modifications and pharmacotherapy. Interventions addressing these fundamentals, such as dynamic blood pressure control below 130/80 mmHg, statin-mediated LDL reduction exceeding 50%, or structured aerobic/resistance training yielding 5-10% body weight loss, demonstrably outperform ancillary modalities in primary prevention cohortsThis hierarchy persists across diverse demographics, affirming that foundational optimization precedes marginal gains from esoteric diagnostics [15,16,17,18].

Layering high-cost prestige interventions atop suboptimal control of sleep architecture, dietary inflammatory load, physical activity volume, or pharmacotherapeutic adherence yields disproportionately small incremental benefits, notwithstanding substantial financial and psychological investment. For instance, executive-grade extracorporeal therapies or peptide stacks may confer transient biomarker shifts, yet fail to supplant the outsized impact of consistent 7-9 hours of restorative sleep or Mediterranean-pattern nutrition on inflammaging markers like IL-6 or hs-CRP. This mismatch highlights a principle of diminishing returns, where technological sophistication amplifies efficacy only within a matrix of mastered essentials [12,13,19,20].

Equally compelling is the equity imperative: as “advanced” wellness modalities evolve into prestige commodities, they exacerbate disparities in cardiometabolic outcomes, privileging those affluent enough to procure status-signalling care while underserved populations, disproportionately burdened by metabolic syndrome, confront barriers to high-yield basics like community-based exercise programs or subsidized pharmacotherapy. Global analyses reveal widening gradients in cardiovascular mortality linked to socioeconomic access gradients, with precision-accessible fundamentals (e.g., polypill strategies) offering scalable equity absent in boutique longevity ecosystems. Reframing prestige as an adjunct to, rather than substitute for, universal prevention is thus ethically and epidemiologically paramount [21,22,23,24].

Precision Medicine as Foundation, not Luxury

Precision medicine transcends the allure of exotic therapies or bespoke interventions; at its essence, it embodies a rigorous framework that harnesses inter-individual variability to sharpen the focus of prevention and treatment, optimizing efficacy across diverse biological contexts. Far from constituting an ancillary luxury, this approach systematically parses genetic, proteomic, and phenotypic heterogeneity to allocate resources toward high-leverage targets, thereby amplifying the precision of clinical decision-making in resource-constrained environments [1,2,25].

In cardiometabolic health, precision medicine operationalizes through targeted modalities that recalibrate preventive strategies:

  • Genomic variants influencing lipid homeostasis or diabetes susceptibility, such as PCSK9 gain-of-function mutations underlying familial hypercholesterolemia or HNF1A alterations in monogenic diabetes, necessitate early, aggressive pharmacotherapy or cascade screening to avert premature atherosclerotic events [26,27].
  • Metabolomic or biomarker signatures, including trimethylamine N-oxide (TMAO) elevations or ceramide ratios, delineate individualized inflammatory or atherogenic patterns amenable to “precision prevention” via tailored dietary exclusions or anti-inflammatory nutraceuticals [28].
  • Digital biomarkers derived from continuous glucose monitoring (CGM), wearable accelerometry, and behavioural analytics unmask temporal dynamics of glycemic lability, sleep fragmentation, and activity chronotypes, informing adaptive interventions like time-restricted feeding synchronized to personal insulin excursions [29,30].

Critically, precision medicine does not supplant lifestyle therapeutics but refines their deployment: stratifying patients by intervention intensity (e.g., intensive multicomponent programs for high polygenic risk versus simplified protocols for low-risk phenotypes) to maximize risk attenuation while minimizing behavioural friction. This foundational role underscores its utility as a force multiplier for conventional care, ensuring that prevention scales equitably across socioeconomic gradients [2,14,31].

AI, Data, and The New “Precision Wellness”

Recent breakthroughs in genomics, panomics (encompassing proteomics, metabolomics, and transcriptomics), and digital phenotyping have exponentially broadened the informational substrate available for individualized therapeutic guidance, transforming disparate data streams into coherent portraits of cardiometabolic vulnerability.These modalities furnish unprecedented granularity, from polygenic risk scores distilling millions of variants to longitudinal phenomic trajectories captured via consumer-grade sensors, thereby surmounting the limitations of siloed biomarkers [31,32,33].

Artificial intelligence (AI) architectures, particularly deep learning ensembles and transformer models, excel at fusing multilayered inputs, genetic arrays, laboratory panels, radiographic sequences, continuous glucose monitoring (CGM) time series, wearable-derived accelerometry and heart rate variability, alongside social determinants of health, to forge dynamic risk stratifications, forecast pharmacodynamic responses, and architect bespoke lifestyle-pharmacologic regimens for primary cardiometabolic prevention.For instance, multimodal AI platforms have demonstrated superior C-indices (0.75-0.85) in forecasting 10-year major adverse cardiovascular events (MACE) by integrating CGM-derived glycemic variability with lipidomic profiles, outperforming conventional scores like ASCVD by 5-10% in net reclassification. Such predictive fidelity enables proactive titration, such as GLP-1 receptor agonist initiation in prediabetic phenotypes exhibiting high postprandial excursions [14,30,34,35,36].

In wellness and biohacking domains, this AI-panomics nexus catalyzes a paradigm shift from dogmatic, population-averaged protocols, epitomized by ubiquitous “16:8 intermittent fasting” mandates to adaptive, feedback-responsive interventions attuned to idiosyncratic metabolic phenotypes, circadian entrainments, and behavioural repertoires.  CGM-AI hybrids, for example, discern personalized glycemic thresholds to modulate feeding windows dynamically, while wearable algorithms optimize recovery protocols based on vagal tone and sleep-stage distributions, yielding 15-25% enhancements in adherence and metabolic flexibility over static regimens [37,38,39].

Nevertheless, AI-augmented precision harbors a peril of commodification: absent deliberate safeguards, these potent capabilities risk rebranding as prestige artifacts, opaque “black-box” longevity dashboards peddled at premium markups, unless engineered with explicit outcome accountability, algorithmic transparency (e.g., SHAP explainability), and scalable accessibility to transcend socioeconomic barriers. Prioritizing federated learning and open-source validation frameworks will be instrumental in actualizing equitable precision wellness [32,40,41].

Case Vignette, Prestige Pathway vs Precision Pathway

Consider a 42-year-old male executive presenting with central adiposity (waist circumference 102 cm), borderline HbA1c (5.9%), and a family history of premature coronary artery disease, who opts for an annual “VIP longevity package” at a boutique clinic. This regimen encompasses whole-body MRI screening, comprehensive omics panels (genomics, proteomics, metabolomics), and serial intravenous nutrient therapies, yet provides scant structured guidance on sustainable nutrition, progressive resistance training, sleep hygiene, or stress mitigation. At 12-month follow-up, body composition (DEXA scan) and glycemic markers remain static, waist unchanged, HbA1c 6.0%—illustrating how diagnostic abundance absent behavioural scaffolding yields negligible cardiometabolic recalibration [13,32,42].

In a contrasting precision pathway, the same patient undergoes targeted risk phenotyping: family history interrogation, standard lipid/glucose panels, selective genomics (e.g., polygenic risk score for dyslipidemia), and 14-day continuous glucose monitoring (CGM) to map postprandial excursions. Data reveal pronounced nocturnal hypoglycemia risk and dawn phenomenon, prompting a structured intervention: chrononutrition (10-hour feeding window aligned to circadian insulin sensitivity), resistance training (3x/week, progressive overload), metformin titration (500 mg nightly), and wearable-guided sleep optimization targeting 7-8 hours consolidated rest. Follow-up at 12 months demonstrates enhanced insulin sensitivity (HOMA-IR reduced 35%), 8% body weight loss, and a 22% decline in 10-year ASCVD risk score, from 7.2% to 5.6% [17,29,43,44].

These parallel vignettes underscore a cardinal principle: therapeutic value inheres not in the ostensible sophistication or fiscal intensity of diagnostic armamentaria, but in their rigorous attunement to quantifiable risk epitopes and seamless translation into monitored, iterative behavioural-pharmacologic change. Prestige trajectories, while sensorially compelling, falter when decoupled from mechanistic fidelity; precision pathways, by contrast, operationalize data as a force multiplier for foundational risk levers, rendering optimization both efficacious and replicable across diverse clinical contexts [14,30].

From Prestige First to Precision First Practice

Clinicians and health systems stand to benefit from adopting a precision-first hierarchy in preventive cardiometabolic and aging wellness practice, systematically prioritizing foundational risk mitigation before escalating to sophisticated diagnostics or therapeutics. This structured paradigm ensures resource allocation aligns with evidence hierarchies, maximizing health span extension while minimizing inefficiency and iatrogenic risk [14].

Master The Fundamentals

Achieve evidence-based control of modifiable risk factors such as systolic blood pressure <130 mmHg, LDL-cholesterol titration per ASCVD risk (e.g., <70 mg/dL for high-risk phenotypes), HbA1c <6.0% via lifestyle/pharmacotherapy, tobacco abstinence, ≥150 min/week moderate-vigorous physical activity, anti-inflammatory nutrition (e.g., Mediterranean pattern), 7-9 hours restorative sleep, and validated mental health screening with intervention as indicated. These levers attenuate 80-90% of attributable cardiovascular burden, forming the indispensable substrate for any advanced optimization [15,17,45].

Stratify Risk Selectively

Deploy validated clinical calculators (Framingham, ASCVD, SCORE2) alongside targeted adjunctive testing, advanced lipid fractionation (Lp(a), apoB), selective imaging (coronary artery calcium scoring for intermediate-risk indeterminacy), or polygenic risk scores, exclusively when results will modify management intensity or therapeutic class [13,43].

Implement Digital Feedback Loops

Leverage continuous glucose monitoring (CGM), consumer wearables (heart rate variability, step cadence, sleep staging), and mobile health applications to generate real-time phenotypic insights, enabling dynamic personalization of behavioural parameters, such as adaptive feeding windows synchronized to glycemic minima or recovery protocols titrated to autonomic balance [32].

Escalate Judiciously to Advanced Modalities:

Reserve high-cost or experimental interventions (exosome therapies, senolytics, hyperbaric protocols) for scenarios demonstrating incremental benefit atop optimized fundamentals, quantified via longitudinal tracking of surrogate endpoints like HOMA-IR, visceral adipose index, or epigenetic age acceleration [46].

For AI health tech innovation, this hierarchy furnishes a blueprint for product architecture: algorithms should embed risk-stratified decision trees, patient journeys must sequence fundamentals-to-precision, and dashboards ought to foreground actionable impact metrics (e.g., risk score delta, adherence trajectories) over prestige-oriented visualizations. Such design philosophy safeguards against commodification, ensuring AI catalyzes equitable precision rather than aesthetic exclusivity [35,40].

Implications for Equity, Ethics, and Implementation

Precision medicine initiatives have faced scrutiny for disproportionately channeling resources into costly technologies, such as expansive genomic sequencing or proprietary AI platforms that predominantly serve socioeconomically advantaged cohorts, potentially entrenching rather than ameliorating health disparities. Paradoxically, their transformative potential in cardiometabolic disease prevention looms largest among high-burden populations, where polygenic predispositions intersect with environmental adversities to amplify susceptibility, underscoring the urgency of inclusive deployment strategies [47,48].

Ethical implementation of precision prevention demands multifaceted safeguards:

Diverse Data Representation:

Curating training datasets reflective of global genomic diversity, socioeconomic gradients, and cardiometabolic phenotypes to mitigate algorithmic bias, as evidenced by PRS performance drops exceeding 20% in underrepresented ancestries [49].

Low-Resource Adaptability:

Engineering tools, mobile CGM interpreters, federated learning apps for seamless integration into primary care or community health outposts, bypassing dependence on tertiary infrastructure [40].

Transparent Messaging:

Articulating that “foundational basics” (hypertension control, tobacco cessation, activity prescription) augmented by selective personalization routinely surpass disjointed, high-profile interventions in risk attenuation metrics [15].

Critically, realigning systemic incentives, reimbursement paradigms favouring outcomes over procedures, business models predicated on health span equity, and consumer narratives elevating sustained risk reduction over experiential prestige proves indispensable to forestalling divergence in cardiometabolic trajectories across privilege strata. This recalibration positions precision not as an elitist enclave, but as a public health accelerant, harnessing individualization to compress morbidity universally [21,32].

Reframing What Looks “Elite”

Precision medicine fundamentally reframes “elite care” not through the lens of exorbitant cost or ostentatious spectacle, but as interventions meticulously calibrated to an individual’s unique biological architecture, contextual realities, and aspirational health objectives, yielding tangible advancements in cardiometabolic resilience and aging trajectories. This paradigm elevates accuracy over extravagance, prioritizing measurable shifts in health span markers, such as insulin sensitivity, vascular compliance, and inflammaging indices, over superficial markers of exclusivity.

In the realms of wellness, biohacking, and preventive metabolic health, the imperative lies in transitioning from prestige-centric pathways, which often prioritize perceptual allure, to precision-first frameworks that harness data integration, artificial intelligence, and multiomics profiling to fortify foundational pillars like glycemic stability, nutrient partitioning, and circadian alignment rather than diverting focus from them. Such a shift democratizes optimization, rendering high-impact strategies accessible beyond elite enclaves.

As clinicians, health tech innovators, and stewards of longevity science, our mandate is to render precision aspirational: illuminating that true luxury resides in an extended, vibrant health span forged through personalized, evidence-grounded daily practices, meticulous chrononutrition, adaptive movement, and restorative recovery rather than ephemeral premium indulgences. This vision positions precision not merely as a methodological advance, but as the ethical pinnacle of human flourishing

Reference

  1. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793-795
  2. National Institutes of Health. What is precision medicine? MedlinePlus Genetics. 2022 [Internet; cited 2026 Feb 24]. Available from: https://medlineplus.gov/genetics/understanding/precisionmedicine/definition/.
  3. Topol EJ. Individualized medicine from prewomb to tomb. Cell. 2014;157(1):241
  4. Roden DM, Wilke RA, Kroemer HK, Stein CM. Pharmacogenomics: the genetics of variable drug responses. N Engl J Med. 2011;365(10):1037-1040.
  5. Wheeler DC, Stefansson K. Precision medicine for cardiometabolic disease: a framework for clinical translation. Lancet Diabetes Endocrinol. 2023;11(12):908-919.
  6. Neeland IJ, Ross R, Després JP, Heitman BL. Precision prevention of cardiometabolic disease. Research Portal Lund University. 2023 [Internet; cited 2026 Feb 24]. Available from: htpps://portal.research. lu.se/en/projects/precision-prevention-of-cardiometabolic-disease/.
  7. Ahuja A. Cardiometabolic precision medicine program. Columbia Cardiology. 2023 [Internet; cited 2026 Feb 24]. Available from: hyyps://www.columbiacardiology.org/research/research-centers-and-programs/cardiometabolic-precision-medicine-program.
  8. Ahuja A. Cardiometabolic precision medicine program. Columbia Cardiology. 2023 [Internet; cited 2026 Feb 24]. Available from:htpps://www.instagram.com/p/DUwMdr6DTfn/.
  9. US Food and Drug Administration. Precision medicine overview. 2025 [Internet; cited 2026 Feb 24]. Available from: https://www.fda.gov/medica-devices/in-vitro-diagnostics/precision-medicine
  10. European Federation of Pharmaceutical Industries and Associations (EFPIA). Development of precision medicine. 2021 [Internet; cited 2026 Feb 24]. Available from: https://www.efpia.eu/about-medicines/development0-of-medicines/precision-medicine/.
  11. Topol EJ. High-definition health care. Nat Med. 2021;27(1):27-29
  12. Ahuja A. The prestige trap: Longevity clinics under scrutiny. Forbes Health. 2025
  13. Greenland P, Blaha MJ, Budoff MJ, Erbel R, Watson KE. Coronary calcium score and cardiovascular risk. J Am Coll Cardiol. 2018;72(4):434-447.
  14. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Circulation. 2019;140(11):e596-e646
  15. Yusuf S, Hawken S, Ôunpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study). Lancet. 2004;364(9438):937-952
  16. Danaei G, Ding EL, Mozaffarian D, et al. The preventable causes of death in the United States. PLoS Med. 2009;6(4):e1000058
  17. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403
  18. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention. Eur Heart J. 2016;37(29):2315-2381
  19. Walker JM, Zakowski L. Sleep and cardiometabolic risk: A review. Sleep Med Rev. 2022;63:101612
  20. Estruch R, Ros E, Salas-Salvadó J, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. N Engl J Med. 2018;378(25):e34
  21. Marmot M. Social determinants of health inequalities. Lancet. 2005;365(9464):1099-1104
  22. Magnani JW, Norby FL, Agarwal SK, et al. Racial Differences in Atrial Fibrillation (from the REasons for Geographic And Racial Differences in Stroke Cohort Study). Am J Cardiol. 2019;123(2):195-200
  23. Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study). Lancet. 2011;378(9798):1231-1243
  24. Wheeler DC, Stefansson K. Precision medicine for cardiometabolic disease: a framework for clinical translation. Lancet Diabetes Endocrinol. 2023;11(12):908-919
  25. Ashley EA. Towards precision medicine. Nat Rev Genet. 2016;17(9):507-522
  26. Abifadel M, Varret M, Rabès JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34(2):154-156
  27. Florez JC. Newly identified loci highlight beta cell dysfunction as a key cause of type 2 diabetes: where are the insulin resistance genes? Diabetologia. 2008;51(7):1100-1110
  28. Tang WH, Kitai T, Hazen SL. Gut microbiota in cardiovascular health and disease. Circ Res. 2017;120(7):1186-1196
  29. Hall KD, Kahan S. Maintenance of lost weight and long-term management of obesity. Med Clin North Am. 2018;102(1):183-197
  30. Roden M, Shulman GI. The integrative biology of type 2 diabetes. Nature. 2019;576(7785):51-60
  31. Hasin Y, Seldin M, Lusis A. Multi-omics approaches to disease. Genome Biol. 2017;18(1):83
  32. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44-56
  33. Luo Y, et al. AI-based multiomics profiling reveals complementary signatures for cardiovascular risk prediction. Nat Commun. 2026;17:68956.
  34. Mohsen F, et al. Artificial Intelligence-Based Methods for Precision Cardiovascular Medicine. Curr Cardiol Rep. 2023;25(10):1315-1326
  35. Rajpurkar P, Chen E, Banerjee O, Topol EJ. AI in health and medicine. Nat Med. 2022;28(1):31-38
  36. Grant JK, et al. Artificial intelligence in cardiovascular health: a case-based review. npj Cardiovasc Health. 2024;1:20
  37. Clova Health. AI-powered CGM for personalized wellness coaching. 2025 [Internet]
  38. Quantum Life. AI-integrated multi-omics for longevity medicine. HKU Spotlight. 2026
  39. Zhang Y, et al. AI-Driven Wearable Bioelectronics in Digital Healthcare. Front Endocrinol. 2025.
  40. Wiens J, et al. Do no harm: a roadmap for responsible machine learning for health care. Nat Med. 2019;25(9):1337-1340
  41. Rieke N, et al. The future of digital health with federated learning. NPJ Digit Med. 2020;3:119
  42. Kontos D, et al. Executive health screening programs: yield and cost-effectiveness. Am J Med. 2022;135(4):512-519
  43. Khera AV, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet. 2018;50(9):1219-1224
  44. Wilkinson MJ, et al. Ten-hour time-restricted eating reduces weight, leptin, and atherogenic lipids. Cell Metab. 2020;31(6):1168-1183.e3
  45. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016;37(29):2315-2381
  46. Justice JN, Ferrucci L, Newman AB, et al. A framework for selection of blood-based biomarkers for geroscience-guided clinical trials. Nat Aging. 2022;2(6):456-465
  47. Martin AR, Kanai M, Kamatani Y, Okada Y, Neale BM, Daly MJ. Clinical use of current polygenic risk scores may exacerbate health disparities. Nat Genet. 2019;51(4):584-591
  48. Hindorff LA, Bonham VL, Brody LC, et al. Precision medicine: a promising foundation for future innovation in health care. Nat Rev Drug Discov. 2018;17(3):199-200
  49. Sirugo G, Williams SM, Tishkoff SA. The missing diversity in human genetic studies. Cell. 2019;177(1):26-31

Discover more from A1C Almanac

Subscribe now to keep reading and get access to the full archive.

Continue reading